Stifel raised the firm’s price target on Dyne Therapeutics to $66 from $41 and keeps a Buy rating on the shares after sitting down with management to discuss their DMD/DM1 programs and what the path forward may look like. Management remains confident FORCE has a differentiated therapeutic index as the company continues to dose higher in both studies with no issues, and continues to believe accelerated paths on dystrophin/splicing remain on the table, the analyst tells investors in a research note. The firm says management continues to engage with regulators and will describe path-to-market for both programs by year-end.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Dyne Therapeutics price target raised to $52 from $48 at Morgan Stanley
- Dyne Therapeutics price target raised to $53 from $43 at Piper Sandler
- Dyne Therapeutics price target raised to $55 from $48 at H.C. Wainwright
- Dyne Therapeutics price target raised to $50 from $42 at Chardan
- Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights